- A study from the Ella Institute of Melanoma, Ramat-Gan, Israel has reported that “MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.”
- This study was published in the 3 June 2013 Journal of Clinical Investigations (IF: 15+) by Prof. Markel G, Nemlich Y and others from Ella Institute of Melanoma, Ramat-Gan, Israel.
- On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNA-based therapy for Metastatic Melanoma: MiRNA-100 and MiRNA-99 increase the expression of RNA-editing enzyme ADAR1(Adenosine Deaminase Acting on RNA) via down regulation of their target genes. This study suggests that miR-100 and miR-99, by suppressing the expression of their target genes, they could inhibit metastatic melanoma. Together, this study suggests that pharmacological formulations containing “MiRNA-100 or MiRNA-99” can be used to treat metastatic human tumors such as metastatic melanoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for Metastatic Melanoma: MiRNA-100 and MiRNA-99 increase the expression of RNA-editing enzyme ADAR1(Adenosine Deaminase Acting on RNA) via down regulation of their target genes, 17/June/2014, 9.27 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
